Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Unique Case Report Describing Association of HLA-DR β1* 0405 with Acute Non-Viral Hepatitis and Aplastic Anemia

Nanda Bhushan, Student, R. Brian Berryman, MD, Afzal Nikaein

Blood (2014) 124 (21): 5155.

https://doi.org/10.1182/blood.V124.21.5155.5155

Published: 2014

Journal Articles

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Andres Forero-Torres, MD, R. Brian Berryman, MD, Ranjana H. Advani, MD, Nancy L. Bartlett, MD, Robert W. Chen, MD, Michelle A. Fanale, MD, Ajay K. Gopal, MD, Owen A. O'Connor, MD, PhD, Randal Olshefski, MD, Scott E. Smith, MD, PhD, FACP, Laurie E. Grove, PA-C, Jeffrey Matous, MD

Blood (2011) 118 (21): 3711.

https://doi.org/10.1182/blood.V118.21.3711.3711

Published: 2011

Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Edward Agura, MD, R. Brian Berryman, MD, Luis Pineiro, MD, Mirjana Tadic-Ovcina, Ryan Woelfel, Estil A. Vance, MD, Joseph W. Fay, MD

Blood (2008) 112 (11): 4320.

https://doi.org/10.1182/blood.V112.11.4320.4320

Published: 2008

Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases.

Edward D. Agura, MD, R. Brian Berryman, MD, Joseph W. Fay, MD, FACP, Luis A. Pineiro, MD, Estil A. Vance, MD, Mirjana Tadic-Ovcina

Blood (2007) 110 (11): 4954.

https://doi.org/10.1182/blood.V110.11.4954.4954

Published: 2007

Journal Articles

Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies Following Sub-Myeloablative Conditioning.

Joseph Fay, MD, Giovanna Saracino, MS, Edward Agura, MD, Brian Berryman, MD, Luis Pineiro, MD, Estil Vance, MD

Blood (2006) 108 (11): 5321.

https://doi.org/10.1182/blood.V108.11.5321.5321

Published: 2006

Journal Articles

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Edward Agura, MD, R. Brian Berryman, MD, Laura Brougher, RN, Barry Cooper, MD, Andrew De Leon, RPh, Joseph Fay, MD, Houston Holmes, MD, Christopher Maisel, MD, Arturo Molina, MD, Luis Pineiro, MD, Giovanna Saracino, MD, Mirjana Tadic-Ovcina, MD, Estil Vance, MD

Blood (2006) 108 (11): 1951.

https://doi.org/10.1182/blood.V108.11.1951.1951

Published: 2006

NARROW

A Unique Case Report Describing Association of HLA-DR β1* 0405 with Acute Non-Viral Hepatitis and Aplastic Anemia

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases.

Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies Following Sub-Myeloablative Conditioning.

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Email alerts

ASH Publications

American Society of Hematology

A Unique Case Report Describing Association of HLA-DR β1* 0405 with Acute Non-Viral Hepatitis and Aplastic Anemia

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases.

Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies Following Sub-Myeloablative Conditioning.

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only